E-LIB Suche - Ergebnisse für: Langenickel, Thomas H

1

Mucosal IFNλ1 mRNA-based immunomodulation effectively reduc..:

Macht, Anna ; Huang, Yiqi ; Reinert, Line S...
EMBO Reports. , 2024

2

On the optimal temporal resolution for phase contrast cardi..:

Santini, Francesco ; Pansini, Michele ; Hrabak-Paar, Maja...
Journal of Cardiovascular Magnetic Resonance. 22 (2020) 1 - p. 72 , 2020

Link: https://doi.org/10.1186/..

3

On the optimal temporal resolution for phase contrast cardi..:

Francesco Santini ; Michele Pansini ; Maja Hrabak-Paar...
http://link.springer.com/article/10.1186/s12968-020-00669-1. , 2020

Link: https://doi.org/10.1186/..

4

The effects of angiotensin receptor neprilysin inhibition b..:

Stinkens, R. ; van der Kolk, B. W. ; Jordan, J....
Scientific Reports. 8 (2018) 1 - p. , 2018

Link: https://doi.org/10.1038/..

5

Developing Drugs for Heart Failure With Reduced Ejection Fr..:

Hinder, Markus ; Yi, B. Alexander ; Langenickel, Thomas H.
Clinical Pharmacology & Therapeutics. 103 (2018) 5 - p. 802-814 , 2018

Link: https://doi.org/10.1002/..

6

Effect of the angiotensin receptor–neprilysin inhibitor sac..:

Ayalasomayajula, Surya ; Schuehly, Uwe ; Pal, Parasar...
British Journal of Clinical Pharmacology. 84 (2018) 5 - p. 926-936 , 2018

Link: https://doi.org/10.1111/..

7

Pharmacodynamic interaction between intravenous nitroglycer..:

Schuehly, Uwe ; Ayalasomayajula, Surya ; Buchbjerg, Jeppe...
European Journal of Clinical Pharmacology. 74 (2018) 9 - p. 1121-1130 , 2018

Link: https://doi.org/10.1007/..

8

Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Me..:

Engeli, Stefan ; Stinkens, Rudi ; Heise, Tim...
Engeli , S , Stinkens , R , Heise , T , May , M , Goossens , G H , Blaak , E E , Havekes , B , Jax , T , Albrecht , D , Pal , P , Tegtbur , U , Haufe , S , Langenickel , T H & Jordan , J 2018 , ' Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension ' , Hypertension , vol. 71 , no. 1 , pp. 70-77 . https://doi.org/10.1161/HYPERTENSIONAHA.117.10224. , 2018

Link: https://cris.maastrichtu..

9

The effect of sacubitril/valsartan compared to olmesartan o..:

Schmieder, Roland E ; Wagner, Frank ; Mayr, Michael...
European Heart Journal. 38 (2017) 44 - p. 3308-3317 , 2017

Link: https://doi.org/10.1093/..

10

Pharmacokinetics and safety of sacubitril/valsartan (LCZ696..:

Kulmatycki, Kenneth M. ; Langenickel, Thomas ; Ng, Wai Hong...
Int. Journal of Clinical Pharmacology and Therapeutics. , 2017

Link: https://doi.org/10.5414/..

11

Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696):..:

Ayalasomayajula, Surya ; Langenickel, Thomas ; Pal, Parasar..
Clinical Pharmacokinetics. 56 (2017) 12 - p. 1461-1478 , 2017

Link: https://doi.org/10.1007/..

12

Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsart..:

Ayalasomayajula, Surya ; Langenickel, Thomas ; Pal, Parasar..
Clinical Pharmacokinetics. 57 (2017) 1 - p. 105-123 , 2017

Link: https://doi.org/10.1007/..

13

Single therapeutic and supratherapeutic doses of sacubitril..:

Langenickel, Thomas H. ; Jordaan, Pierre ; Petruck, Jesika...
European Journal of Clinical Pharmacology. 72 (2016) 8 - p. 917-924 , 2016

Link: https://doi.org/10.1007/..

14

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/..:

Kobalava, Zhanna ; Kotovskaya, Yulia ; Averkov, Oleg...
Cardiovascular Therapeutics. 34 (2016) 4 - p. 191-198 , 2016

Link: https://doi.org/10.1111/..

15

Effect of food on the oral bioavailability of the angiotens..:

Ayalasomayajula, Surya ; Langenickel, Thomas ; Chandra, Priya...
Int. Journal of Clinical Pharmacology and Therapeutics. 54 (2016) 12 - p. 1012-1018 , 2016

Link: https://doi.org/10.5414/..